Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 8/20 | 1.00 |
| ▸ | CYP4Z1 | Q86W10 | 5/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | MGAM | O43451 | 1/20 | 0.53 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SI | P14410 | 1/20 | 0.53 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12593863 | 1.00 | ASAH1 (1.00) | ASAH1CYP4Z1MGLLMGAMAMY1A | |
| SCHEMBL13875221 | 1.00 | ASAH1 (1.00) | ASAH1CYP4Z1MGLLMGAMAMY1A | |
| SCHEMBL14632207 | 0.87 | ASAH1 (0.77) | ASAH1CYP4Z1MGLLMGAMAMY1A | |
| SCHEMBL20150832 | 0.83 | ASAH1 (0.71) | ASAH1MGLLMGAMAMY1AGAA | |
| SCHEMBL426726 | 0.83 | ASAH1 (1.00) | ASAH1MGLLMGAMAMY1AGAA | |
| SCHEMBL12594140 | 0.83 | ASAH1 (0.70) | ASAH1MGLL | |
| SCHEMBL12594139 | 0.83 | ASAH1 (0.70) | ASAH1MGLL | |
| SCHEMBL25504900 | 0.82 | ASAH1 (0.70) | ASAH1MGLLMGAMAMY1AGAA | |
| SCHEMBL12594148 | 0.82 | ASAH1 (0.69) | ASAH1MGLLMGAMAMY1AGAA | |
| SCHEMBL12594147 | 0.82 | ASAH1 (0.69) | ASAH1CYP4Z1MGLLMGAMAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | ASAH1 3/4885CYP4Z1 1727/4885MGLL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.